Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Observational

Evaluation of Interactions and Group Processes in Multidisciplinary Tumor Boards in Gynecologic Oncology

NCT07645716 · tracked via the Priya Life Science Italy tracker
Phase
Observational
Started
2026-07-13
Last updated
2026-06-12

Condition(s) studied

Ovarian NeoplasmsUterine Neoplasms

Investigational drug(s) / intervention(s)

Online Survey Assessment of Tumor Board Group Dynamics

Online Survey Assessment of Tumor Board Group Dynamics: Participants will complete an online survey after each ovarian and uterine cancer multidisciplinary tumor board meeting. The survey assesses group dynamics and decision-making processes, including team cohesion, minority dissent, team learning, task interdependence, collective information processing, team communication, individual information processing, and psychological safety. No clinical, pharmacological, diagnostic, surgical, radiation, behavioral, or therapeutic intervention will be administered.

Study summary

Study Title Group Dynamics Evaluation in Gynecologic Multidisciplinary Tumor Boards - GOLD Study

Background and Rationale Multidisciplinary Tumor Boards are central to complex oncologic decision-making. In gynecologic oncology, clinical decisions often require the integration of knowledge from different specialties, including surgery, medical oncology, radiology, pathology, radiation oncology, and other relevant disciplines. These teams function not only as groups of specialists but also as collective decision-making systems, where communication, collaboration, information sharing, psychological safety, and group dynamics may influence the quality of clinical discussion and final recommendations.

Study Objective The GOLD Study aims to investigate the decision-making process and group dynamics within ovarian and uterine cancer Multidisciplinary Tumor Boards. The study will assess how communication patterns, collaboration, minority dissent, team cohesion, team learning, task interdependence, collective information processing, individual information processing, and psychological safety contribute to Tumor Board performance.

Study Design This is a single-center, prospective, longitudinal observational study involving physicians participating in ovarian and uterine cancer Multidisciplinary Tumor Boards, either in person or online.

Methods At the end of each Tumor Board meeting, participating physicians will complete an online survey using Microsoft Forms. The questionnaire was developed within a scientific collaboration with the Department of Business and Management of LUISS Guido Carli University and includes validated measurement scales derived from the literature. In addition, data on team composition and participation will be collected for each meeting.

Statistical Analysis Survey data and participation data will be analyzed using descriptive statistics, inferential methods, and social network analysis. Network measures such as density and centralization indices will be used to evaluate the structure of interactions and participation over time. Statistical analyses will be performed using Stata, R, and UCINET where appropriate.

Target Population and Sample Size The target population includes physicians involved in the clinical decision-making process during ovarian and uterine cancer Tumor Boards. A total of approximately 400 questionnaires is planned, based on the rule of thumb of at least 10 respondents per questionnaire variable.

Study Duration The expected study duration is six months.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Physicians participating in the clinical decision-making process within ovarian and uterine cancer multidisciplinary tumor board meetings. * Participation in the full tumor board session. * Participation either in person or online. * Representation of at least one relevant specialty or role involved in the clinical decision-making process. Exclusion Criteria: * Partial attendance at the ovarian and uterine cancer multidisciplinary tumor board session. * Trainees or other attendees not directly involved in the clinical decision-making process. * Physicians whose specialty contribution consists of occasional consultation for less than 50% of the study period. * Incomplete survey completion. * If more than one member represents the same specialty or role, participants with lower participation in the clinical decision-making process may be excluded.

Primary outcome measure(s)

  • Decision-Making and Group Dynamics in Gynecologic Tumor Boards — 6-month study period
    Assessment of the decision-making process and group dynamics within ovarian and uterine cancer multidisciplinary tumor board meetings. The outcome will be measured using an online survey completed by participating physicians at the end of each meeting. The survey evaluates team cohesion, minority dissent, team learning, task interdependence, collective information processing, team communication, individual information processing, and team psychological safety.

Trial sites (1)

FacilityCityRegionStatus
Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC Ginecologia Oncologica Roma Roma
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07645716 on ClinicalTrials.gov ↗ ← All trials in Italy